Home' Australian Pharmacist : Australian Pharmacist August 2014 Contents Australian Pharmacist August 2014 I ©Pharmaceutical Society of Australia Ltd.
Sano and Janssen join
forces on diabetes
Sanofi-Aventis (Sanofi) and Janssen-Cilag
have joined forces to co-promote
their respective diabetes treatments
Apidra (insulin glulisine) and Invokana
(canagliflozin) in Australia.
Chris Hourigan, Managing Director,
Janssen Australia and New Zealand said:
'This agreement brings together our oral
diabetes treatment Invokana, with Sanofi's
experience in assisting people living with
diabetes to manage their condition.
'In a disease area where there is significant
unmet need this agreement presents our
opportunity to make a real difference to
Australians living with type 2 diabetes,'
Laurie McAllister, Managing Director,
Sanofi Australia and New Zealand, said:
'At Sanofi, we are proud of our 90-year
history of helping people with diabetes.
'By combining both companies'
experiences in the early and later stages
of type 2 diabetes management, we will
help address the unmet medical needs of
the increasing number of Australians faced
with this complex disease. Traditionally
pharmaceutical companies have looked
to product launches to expand their
healthcare footprint. Our agreement with
Janssen brings together our collective
expertise, and gives us an opportunity
to have more robust and value-added
conversations with the medical community
to enhance the management of type 2
diabetes in this country,' Mr McAllister said.
Diabetes is the fastest-growing chronic
disease in Australia1. At least 1.5 million
Australians have diabetes, and it is forecast
to become the number one burden of
disease in Australia in the next five years1.
Mr McAllister said that the agreement
gave both companies the opportunity
to offer a more comprehensive suite of
treatments to healthcare professionals
and through them to the many
thousands of Australians with diabetes.
New super guarantee rate
The Australian Taxation Office (ATO) has
reminded employers they need to increase
the compulsory minimum super payments
they make on behalf of eligible employees.
Emma Haines, ATO Assistant Commissioner,
said the super guarantee rate increased
from 9.25% to 9.5% on 1 July.
'Super contributions are calculated on
the date you pay your employees. If this
date was on 1 July or after, then you will
need to use the new super guarantee
rate,' Ms Haines said.
'Employers can use the ATO's online
superannuation guarantee contributions
calculator to work out how much super
they must contribute for eligible workers.'
Small businesses are encouraged
to use the ATO's free Small Business
Superannuation Clearing House service
to help meet their super guarantee
obligations. The Small Business
Superannuation Clearing House lets you
pay your superannuation contributions
in one transaction, to a single location;
helping to make the process easier.
'If you have 19 employees or fewer,
you can use this free service to pay your
super contributions in one transaction,'
Ms Haines said.
For more information about super
guarantee visit: www.ato.gov.au/
employersuper or seek help from your
superannuation service provider.
MA submits code of conduct
Medicines Australia (MA) has applied to
the Australian Competition and Consumer
Commission for authorisation of the 18th
Edition of its Code of Conduct.
MA Chief Executive, Dr Brendan Shaw,
said: 'Medicines Australia's member
companies are taking the lead in setting
new standards of transparency in
Australia's health sector with this new
Code. Interactions between healthcare
professionals and pharmaceutical
companies are essential for ensuring that
patients have the best care. They ensure
healthcare professionals have up to date
and comprehensive information about
'This new Code sets new standards in
the transparency in these interactions
which is unprecedented in the Australian
'While the journey of delivering greater
transparency isn't easy, these new
transparency measures are an important
step forward for industry, healthcare
professionals and importantly Australian
'We want to work in partnership with
healthcare professionals, consumers,
other industry sectors and the broader
community to make this new era of
However, the new Code was criticised by
the Consumers Health Forum (CHF).
Consumer Health Forum HF Chief
Executive Officer, Adam Stankevicius,
said the forum was disappointed MA
decided to reject the advice of its
own transparency working group that
recommended a more rigorous approach
in its proposed Code of Conduct to the
detailed reporting of payments and other
perks provided to medical practitioners
by drug companies.
'As a result, senior medical experts will
still be able to receive tens of thousands
of dollars in speakers' fees, sponsored
travel and other perks from a drug
company in return for giving talks about
that company's product, without these
individual practitioner payments being
'Such undisclosed perks and
remuneration undermine the
independence of medical practitioners
and the confidence of consumers in
relation to medicines prescribing,' he said.
According to MA the new code will
introduce expanded transparency
reporting that will require its member
companies to report on an individual
basis a wide range of payments and
transfers of value to individual healthcare
professionals, as well as sponsorships of
third party educational meetings and
Links Archive Australian Pharmacist September 2014 Australian Pharmacist July 2014 Navigation Previous Page Next Page